ArticleFrontiers in oncology2026
Mechanistic insights into voriconazole-exacerbated selpercatinib-induced thrombocytopenia: a pharmacokinetic interaction case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper reports a case of Grade IV thrombocytopenia in a 65-year-old male patient with advanced lung cancer after 4 days of concurrent treatment with selpercatinib and voriconazole. The clinical pharmacist attributed the thrombocytopenia to voriconazole exacerbating the hematological toxicity of selpercatinib and thus stopped selpercatinib and voriconazole treatment sequentially; the patient was given recombinant human thrombopoietin to raise platelets. When the platelet count returned to normal and voriconazole was discontinued, selpercatinib was restarted at a reduced dose and gradually titrated back to the original therapeutic dose. Subsequent treatment did not have any further adverse reactions. This case suggests that doctors and clinician pharmacists should be aware of the potential interaction between selpercatinib and voriconazole, avoid the use of CYP3A4 inhibitors during selpercatinib treatment, and pay attention to dose adjustment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.